Evidence map›Paper›PMID 27589252›Full record

Trial reportDiabetic medicine : a journal of the British Diabetic Association2017

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.

H W Rodbard, B W Bode, S B Harris, L Rose, L Lehmann, H Jarlov, J Thurman, Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetic medicine : a journal of the British Diabetic Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01618162. Cited by 60 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01618162 phase3completed

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Ran2012Enrolled435Registered outcomes7Posted comparisons1ConditionsDiabetes, Diabetes Mellitus, Type 2Armsinsulin degludec/liraglutide, Placebo
PMID 28332144other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

H W RodbardEndocrine and Metabolic Consultants, Rockville, MD, USA.
B W BodeAtlanta Diabetes Associates, Atlanta, GA, USA.
S B HarrisCentre for Studies in Family Medicine, London, ON, Canada.
L RoseInstitute for Diabetes Research, Münster, Germany.
L LehmannNovo Nordisk A/S, Søborg, Denmark.
H JarlovNovo Nordisk A/S, Søborg, Denmark.
J ThurmanSSM - Medical Group, St. Louis, MO, USA.
Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the safety and efficacy of insulin degludec/liraglutide (IDegLira), a novel combination product, as add-on therapy for people with Type 2 diabetes uncontrolled on sulphonylurea therapy.

methodsIn this 26-week, double-blind trial, adults with Type 2 diabetes [HbA

resultsThe mean HbA

conclusionsIDegLira can be used in people uncontrolled with sulphonylurea ± metformin to improve efficacy with a safety profile in line with previous DUAL trials.

Indexed as

AgedBlood GlucoseDiabetes Mellitus, Type 2Double-Blind MethodDrug CombinationsDrug Therapy, CombinationFemaleGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulin, Long-ActingLiraglutideMaleMetforminMiddle AgedBlood GlucoseDrug CombinationsGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsIDegLiraInsulin, Long-ActingLiraglutideMetforminSulfonylurea Compounds

Identifiers

PMID27589252
PMCPMC5811787

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.